Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research (original) (raw)

• Runyon, B. A. Care of patients with ascites. N. Engl. J. Med. 330, 337–342 (1994).
  Article CAS PubMed Google Scholar
• Parsons, S. L., Lang, M. W. & Steele, R. J. Malignant ascites: a 2-year review from a teaching hospital. Eur. J. Surg. Oncol. 22, 237–239 (1996).
  Article CAS PubMed Google Scholar
• Ayantunde, A. & Parsons, S. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann. Oncol. 18, 945–949 (2007).
  Article CAS PubMed Google Scholar
• Garrison, R. N., Kaelin, L. D., Galloway, R. H. & Heuser, L. S. Malignant ascites. Clinical and experimental observations. Ann. Surg. 203, 644–651 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Howlader, N. et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute [online], (2012).
• Lopez, R. I. et al. Prognostic factor analysis, for patients with no evidence of disease after initial chemotherapy for advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 6, 8–14 (1996).
  Article Google Scholar
• Tan, D. S., Agarwal, R. & Kaye, S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925–934 (2006).
  Article PubMed Google Scholar
• Bagnato, A. & Rosano, L. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185, 85–94 (2007).
  Article CAS PubMed Google Scholar
• Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255–288 (2001).
  CAS PubMed Google Scholar
• Gardner, M. J., Catterall, J. B., Jones, L. M. & Turner, G. A. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin. Exp. Metastasis 14, 325–334 (1996).
  Article CAS PubMed Google Scholar
• Strobel, T., Swanson, L. & Cannistra, S. A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 57, 1228–1232 (1997).
  CAS PubMed Google Scholar
• Wagner, B. J. et al. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int. J. Oncol. 39, 1593–1600 (2011).
  CAS PubMed Google Scholar
• Rump, A. et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279, 9190–9198 (2004).
  Article CAS PubMed Google Scholar
• Gubbels, J. A. et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 566, 50 (2006).
  Article CAS Google Scholar
• Renkin, E. M. Some consequences of capillary permeability to macromolecules: Starling's hypothesis reconsidered. Am. J. Physiol. 250, H706–710 (1986).
  CAS PubMed Google Scholar
• Mutsaers, S. E. The mesothelial cell. Int. J. Biochem. Cell Biol. 36, 9–16 (2004).
  Article CAS PubMed Google Scholar
• Mutsaers, S. E. Mesothelial cells: their structure, function and role in serosal repair. Respirology 7, 171–191 (2002).
  Article PubMed Google Scholar
• von Recklinghausen, F. T. Zur fettre sorption. Arch. Pathol. Anat. Physiol. 2666, 172 (1863).
  Article Google Scholar
• Sodek, K. L., Murphy, K. J., Brown, T. J. & Ringuette, M. J. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 31, 397–414 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Holm-Nielsen, P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol. Microbiol. Scand. 33, 10–21 (1953).
  Article CAS PubMed Google Scholar
• Feldman, G. B., Knapp, R. C., Order, S. E. & Hellman, S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 32, 1663–1666 (1972).
  CAS PubMed Google Scholar
• Nagy, J. A., Herzberg, K. T., Dvorak, J. M. & Dvorak, H. F. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 53, 2631–2643 (1993).
  CAS PubMed Google Scholar
• Garrison, R. N., Galloway, R. H. & Heuser, L. S. Mechanisms of malignant ascites production. J. Surg. Res. 42, 126–132 (1987).
  Article CAS PubMed Google Scholar
• Hirabayashi, K. & Graham, J. Genesis of ascites in ovarian cancer. Am. J. Obstet. Gynecol. 106, 492–497 (1970).
  Article CAS PubMed Google Scholar
• Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
  Article CAS PubMed Google Scholar
• Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9–22 (1999).
  Article CAS PubMed Google Scholar
• Geva, E. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil. Steril. 74, 429–438 (2000).
  Article CAS PubMed Google Scholar
• Zebrowski, B. K. et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6, 373–378 (1999).
  Article CAS PubMed Google Scholar
• Barton, D. P. et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin. Cancer Res. 3, 1579–1586 (1997).
  CAS PubMed Google Scholar
• Kassim, S. K. et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin. Biochem. 37, 363–369 (2004).
  Article CAS PubMed Google Scholar
• Paley, P. J. et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80, 98–106 (1997).
  Article CAS PubMed Google Scholar
• Bamias, A. et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol. Oncol. 108, 421–427 (2008).
  Article CAS PubMed Google Scholar
• Santin, A. D. et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur. J. Gynaecol. Oncol. 20, 177–181 (1999).
  CAS PubMed Google Scholar
• Schumacher, J. J. et al. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 67, 3683–3690 (2007).
  Article CAS PubMed Google Scholar
• Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
  CAS PubMed Google Scholar
• Mesiano, S., Ferrara, N. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153, 1249–1256 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Yukita, A., Asano, M., Okamoto, T., Mizutani, S. & Suzuki, H. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res. 20, 155–160 (2000).
  CAS PubMed Google Scholar
• Herr, D. et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol. Oncol. 127, 210–216 (2012).
  Article CAS PubMed Google Scholar
• Rodewald, M. et al. Regulation of tight junction proteins occludin and claudin 5 in the primate ovary during the ovulatory cycle and after inhibition of vascular endothelial growth factor. Mol. Hum. Reprod. 13, 781–789 (2007).
  Article CAS PubMed Google Scholar
• Saitou, M. et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 11, 4131–4142 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Dejana, E. Endothelial cell-cell junctions: happy together. Nature Rev. Mol. Cell Biol. 5, 261–270 (2004).
  Article CAS Google Scholar
• Takahashi, A., Kondoh, M., Kodaka, M. & Yagi, K. Peptides as tight junction modulators. Curr. Pharm. Des. 17, 2699–2703 (2011).
  Article CAS PubMed Google Scholar
• Nitta, T. et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161, 653–660 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F. & Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97–132 (1999).
  CAS PubMed Google Scholar
• Esser, S., Lampugnani, M. G., Corada, M., Dejana, E. & Risau, W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111, 1853–1865 (1998).
  CAS PubMed Google Scholar
• Horiuchi, A. et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 α and cell cycle-related molecules in ovarian cancer cells. Anticancer Res. 22, 2697–2702 (2002).
  CAS PubMed Google Scholar
• Hu, Y. L. et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl Cancer Inst. 93, 762–768 (2001).
  Article CAS PubMed Google Scholar
• Kulbe, H. et al. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585–592 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Salani, D. et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. 157, 1537–1547 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, R. A. et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63, 906–911 (2003).
  CAS PubMed Google Scholar
• Stadlmann, S. et al. Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol. Oncol. 97, 784–789 (2005).
  Article CAS PubMed Google Scholar
• Belotti, D. et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63, 5224–5229 (2003).
  CAS PubMed Google Scholar
• Chen, Y., Gou, X., Ke, X., Cui, H. & Chen, Z. Human tumor cells induce angiogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS ONE 766, e40965 (2012).
  Article CAS Google Scholar
• Liu, L. Z. et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 41, 1521–1533 (2006).
  Article CAS PubMed Google Scholar
• Matei, D. et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol. Ther. 6, 1951–1959 (2007).
  Article CAS PubMed Google Scholar
• Liao, S. et al. TGF-β blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin. Cancer Res. 17, 1415–1424 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mills, G. B., May, C., McGill, M., Roifman, C. M. & Mellors, A. A. Putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 48, 1066–1071 (1988).
  CAS PubMed Google Scholar
• Fang, X. et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem. 279, 9653–9661 (2004).
  Article CAS PubMed Google Scholar
• Murph, M. M. et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 4, e5583 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Jankowski, M. Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Res. 19, 48–57 (2011).
  Google Scholar
• Bast, R. C. Jr, Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nature Rev. Cancer 9, 415–428 (2009).
  Article CAS Google Scholar
• Mills, G. B. & Moolenaar, W. H. The emerging role of lysophosphatidic acid in cancer. Nature Rev. Cancer 3, 582–591 (2003).
  Article CAS Google Scholar
• Abrahams, V. M. et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 63, 5573–5581 (2003).
  CAS PubMed Google Scholar
• Bjorge, L. et al. Ascitic complement system in ovarian cancer. Br. J. Cancer 92, 895–905 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Webb, T. J. et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res. 72, 3744–3752 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Milliken, D., Scotton, C., Raju, S., Balkwill, F. & Wilson, J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8, 1108–1114 (2002).
  CAS PubMed Google Scholar
• Guo, Y. et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 16, 5759–5769 (2010).
  Article CAS PubMed Google Scholar
• Matte, I., Lane, D., Laplante, C., Rancourt, C. & Piche, A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am. J. Cancer Res. 2, 566–580 (2012).
  CAS PubMed PubMed Central Google Scholar
• Penson, R. T. et al. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 10, 33–41 (2000).
  Article PubMed Google Scholar
• Kryczek, I., Grybos, M., Karabon, L., Klimczak, A. & Lange, A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br. J. Cancer 82, 621–628 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, S., Robinson, J. B., DeGuzman, A., Bucana, C. D. & Fidler, I. J. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60, 5334–5339 (2000).
  CAS PubMed Google Scholar
• Yoneda, J. et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Institute 90, 447–454 (1998).
  Article CAS Google Scholar
• Obata, N., Tamakoshi, K., Shibata, K., Kikkawa, F. & Tomoda, Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human carcinoma. Anticancer Res. 17, 337–342 (1997).
  CAS PubMed Google Scholar
• Woolery, K. T. & Kruk, P. A. Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. Obstet. Gynecol. Int. 35, 84–93 (2011).
  Google Scholar
• Nilsson, M. B., Langley, R. R. & Fidler, I. J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 65, 10794–10800 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Alberti, C. et al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 31, 4139–4149 (2011).
  Article PubMed CAS Google Scholar
• Lane, D., Matte, I., Rancourt, C. & Piche, A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 1166, 210 (2011).
  Article CAS Google Scholar
• Naldini, A. et al. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thromb. Haemost. 106, 705–711 (2011).
  Article CAS PubMed Google Scholar
• Gubbels, J. A. et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 966, 11 (2010).
  Article CAS Google Scholar
• Sica, A., Saccani, A. & Mantovani, A. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2, 1045–1054 (2002).
  Article CAS PubMed Google Scholar
• Hagemann, T. et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176, 5023–5032 (2006).
  Article CAS PubMed Google Scholar
• Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540–550 (2004).
  Article CAS Google Scholar
• Wang, E. et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin. Cancer Res. 11, 113–122 (2005).
  CAS PubMed Google Scholar
• Lin, Y. G. et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109, 332–340 (2007).
  Article CAS PubMed Google Scholar
• Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000–2008 (2002).
  Article CAS PubMed Google Scholar
• Rosen, D. G. et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107, 2730–2740 (2006).
  Article CAS PubMed Google Scholar
• Lane, D., Robert, V., Grondin, R., Rancourt, C. & Piche, A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int. J. Cancer 121, 1227–1237 (2007).
  Article CAS PubMed Google Scholar
• Lane, D., Goncharenko-Khaider, N., Rancourt, C. & Piche, A. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29, 3519–3531 (2010).
  Article CAS PubMed Google Scholar
• Goncharenko-Khaider, N., Matte, I., Lane, D., Rancourt, C. & Piche, A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol. Cancer 1166, 84 (2012).
  Article CAS Google Scholar
• Peart, T. M., Correa, R. J., Valdes, Y. R., Dimattia, G. E. & Shepherd, T. G. BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation. Clin. Exp. Metastasis 29, 293–313 (2012).
  Article CAS PubMed Google Scholar
• Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27, 1419–1425 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• De Placido, S. et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22, 2635–2642 (2004).
  Article CAS PubMed Google Scholar
• du Bois, A. et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24, 1127–1135 (2006).
  Article CAS PubMed Google Scholar
• Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. New Engl. J. Med. 365, 2484–2496 (2011).
  Article CAS PubMed Google Scholar
• Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl. J. Med. 365, 2473–2483 (2011).
  Article CAS PubMed Google Scholar
• Kristensen, G. P. et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J. Clin. Oncol. Abstr. 29, LBA5006 (2011).
  Article Google Scholar
• Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–2045 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pujade-Lauraine, E. et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J. Clin. Oncol. Abstr. 30, LBA5002 (2012).
  Article Google Scholar
• Sennino, B. & McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nature Rev. Cancer 12, 699–709 (2012).
  Article CAS Google Scholar
• Runyon, B. A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 49, 2087–2107 (2009).
  Article PubMed Google Scholar
• Lee, C. W., Bociek, G. & Faught, W. A survey of practice in management of malignant ascites. J. Pain Symptom Manage. 16, 96–101 (1998).
  Article CAS PubMed Google Scholar
• Becker, G., Galandi, D. & Blum, H. E. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer 42, 589–597 (2006).
  Article PubMed Google Scholar
• Pockros, P. J., Esrason, K. T., Nguyen, C., Duque, J. & Woods, S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103, 1302–1306 (1992).
  Article CAS PubMed Google Scholar
• Cavazzoni, E., Bugiantella, W., Graziosi, L., Franceschini, M. S. & Donini, A. Malignant ascites: pathophysiology and treatment. Int. J. Clin. Oncol. 31 Mar 2012 (doi:10.1007/s10147-012-0396-6).
• Kalambokis, G. et al. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrol. Dial. Transplant. 20, 1623–1629 (2005).
  Article CAS PubMed Google Scholar
• Jatoi, A. et al. A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology 82, 315–320 (2012).
  Article CAS PubMed Google Scholar
• Dedrick, R. L., Myers, C. E., Bungay, P. M. & DeVita, V. T. Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1–11 (1978).
  CAS PubMed Google Scholar
• Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006).
  Article CAS PubMed Google Scholar
• Ostrowski, M. J. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 57, 721–727 (1986).
  Article CAS PubMed Google Scholar
• Maiche, A. G. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anticancer Drugs 5, 305–308 (1994).
  Article CAS PubMed Google Scholar
• Link, K. H. et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg. Oncol. Clin. N. Am. 12, 865–872 (2003).
  Article CAS PubMed Google Scholar
• Schilsky, R. L. et al. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J. Clin. Oncol. 8, 2054–2061 (1990).
  Article CAS PubMed Google Scholar
• Mackey, J. R., Wood, L., Nabholtz, J., Jensen, J. & Venner, P. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J. Pain Symptom Manage. 19, 193–199 (2000).
  Article CAS PubMed Google Scholar
• Stuart, G. C., Nation, J. G., Snider, D. D. & Thunberg, P. Intraperitoneal interferon in the management of malignant ascites. Cancer 71, 2027–2030 (1993).
  Article CAS PubMed Google Scholar
• Rath, U. et al. Effect of intraperitoneal recombinant human tumour necrosis factor α on malignant ascites. Eur. J. Cancer 27, 121–125 (1991).
  Article CAS PubMed Google Scholar
• Heiss, M. M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int. J. Cancer 127, 2209–2221 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ott, M. G. et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int. J. Cancer 130, 2195–2203 (2012).
  Article CAS PubMed Google Scholar
• Beattie, G. J. & Smyth, J. F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. 4, 1899–1902 (1998).
  CAS PubMed Google Scholar
• Numnum, T. M., Rocconi, R. P., Whitworth, J. & Barnes, M. N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102, 425–428 (2006).
  Article CAS PubMed Google Scholar
• El-Shami, K., Elsaid, A. & El-Kerm, Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J. Clin. Oncol. 25, 9043 (2007).
  Google Scholar
• Hamilton, C. A. et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol. Oncol. 111, 530–532 (2008).
  Article CAS PubMed Google Scholar
• Bellati, F. et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest. New Drugs 28, 887–894 (2010).
  Article CAS PubMed Google Scholar
• Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. 99, 11393–11398 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Colombo, N. et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol. Oncol. 125, 42–47 (2012).
  Article CAS PubMed Google Scholar
• Gotlieb, W. H. et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 13, 154–162 (2012).
  Article CAS PubMed Google Scholar
• LeVeen, H. H. et al. Peritoneo-venous shunting for ascites. Ann. Surg. 180, 580–591 (1974).
  Article CAS PubMed PubMed Central Google Scholar
• Mamada, Y. et al. Peritoneovenous shunts for palliation of malignant ascites. J. Nippon Med. Sch. 74, 355–358 (2007).
  Article PubMed Google Scholar
• White, M. A., Agle, S. C., Padia, R. K. & Zervos, E. E. Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era. Am. Surg. 77, 1070–1075 (2011).
  PubMed Google Scholar
• Saiz-Mendiguren, R. et al. Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter. Radiologia 52, 541–545 (2010).
  Article CAS PubMed Google Scholar
• Fleming, N. D., Alvarez-Secord, A., Von Gruenigen, V., Miller, M. J. & Abernethy, A. P. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J. Pain Symptom Manage. 38, 341–349 (2009).
  Article PubMed Google Scholar
• Tapping, C. R., Ling, L. & Razack, A. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. Br. J. Radiol 85, 623–628 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kmietowicz, Z. Cancer patients should have access to device to treat fluid retention at home, says NICE. BMJ 344, e2272 (2012).
  Article PubMed Google Scholar
• Puiffe, M.-L. et al. Characterization of ovarian cancer ascites on cell. Invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9, 820–829 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, J. m. & Kohn, E. C. Proteomics as a guiding tool for more effective personalized therapy. Ann. Oncol. 21, 205–210 (2010).
  Article Google Scholar
• Morozova, O. & Marra, M. A. Applications of next-generation sequencing technologies in functional genomics. Genomics 92, 255–264 (2008).
  Article CAS PubMed Google Scholar
• Hetland, T. E. et al. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum. Pathol. 42, 1019–1026 (2011).
  Article CAS PubMed Google Scholar
• Gillet, J.-P. et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol. Pharm. 8, 2080–2088 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Shepherd, T. G., Thériault, B. L., Campbell, E. J. & Nachtigal, M. W. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nature Protoc. 1, 2643–2649 (2007).
  Article CAS Google Scholar
• Hu, L., McArthur, C. & Jaffe, R. B. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br. J. Cancer 102, 1276–1283 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mukhopadhyay, A. et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344–2351 (2010).
  Article CAS PubMed Google Scholar
• Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512–2519 (2010).
  Article CAS PubMed Google Scholar
• Elattar, A. et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol. Oncol. 124, 142–147 (2012).
  Article CAS PubMed Google Scholar
• Carden, C. P. et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol. Cancer Ther. 11, 1609–1617 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rizzo, S. et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10, 325–335 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Moserle, L. et al. The side population of ovarian cancer cells is a primary target of IFN-α antitumor effects. Cancer Res. 68, 5658–5668 (2008).
  Article CAS PubMed Google Scholar
• Meirelles, K. et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc. Natl Acad. Sci. USA 109, 2358–2363 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Latifi, A. et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE 766, e46858 (2012).
  Article CAS Google Scholar
• Davidson, B. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin. Cancer Res. 12, 791–799 (2006).
  Article CAS PubMed Google Scholar
• Yap, T. A., Carden, C. P. & Kaye, S. B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Rev. Cancer 9, 167–181 (2009).
  Article CAS Google Scholar
• Lee, J.-M., Han, J. J., Altwerger, G. & Kohn, E. C. Proteomics and biomarkers in clinical trials for drug development. J. Proteomics 74, 2632–2641 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Runyon, B. A. et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann. Intern. Med. 117, 215–220 (1992).
  Article CAS PubMed Google Scholar
• Sheid, B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett. 62, 153–158 (1992).
  Article CAS PubMed Google Scholar
• Starling, E. H. On the absorption of fluids from the connective tissue spaces. J. Physiol. 19, 312–326 (1896).
  Article CAS PubMed PubMed Central Google Scholar
• Cattau, E. L. Jr, Benjamin, S. B., Knuff, T. E. & Castell, D. O. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 247, 1164–1166 (1982).
  Article PubMed Google Scholar
• Inadomi, J., Cello, J. P. & Koch, J. Ultrasonographic determination of ascitic volume. Hepatology 24, 549–551 (1996).
  Article CAS PubMed Google Scholar
• Akriviadis, E. A. Hemoperitoneum in patients with ascites. Am. J. Gastroenterol. 92, 567–575 (1997).
  CAS PubMed Google Scholar
• von Riedenauer, W. B., Janjua, S. A., Kwon, D. S., Zhang, Z. & Velanovich, V. Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. J. Med. Case Rep. 166, 150 (2007).
  Article Google Scholar